Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Launches Survey to Gauge COVID-19 Impact on Drug Supplies
March 27, 2020
- Generic Use Rate at 77.1% in October-December 2019: JGA
March 27, 2020
- Japan Pharma Lobbies Hammer Out One-Year Term Extensions for Their Leaders
March 24, 2020
- JPMA Chief Fires Back at Health Policy Advisor’s “Plenty of Financial Strength” Comment
March 23, 2020
- JPMA Members Increasing Drug Stockpiles to Deal with COVID-19, Need Govt Support: Chief
March 23, 2020
- Japanese Drug Firms Providing APIs for NIID Screening for COVID-19: JPMA Survey
March 19, 2020
- Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
March 16, 2020
- India’s API Export Curb Could Eventually Affect At Least 2 Firms, FPMAJ Finds
March 10, 2020
- Japan Infectious Diseases Society Shares Latest Knowledge on Antivirals against COVID-19
February 28, 2020
- Japan Pharma Lobbies Likely to Retain Chiefs as Off-Year Re-Pricing Debate Looms
February 21, 2020
- PhRMA Japan Continues Push Against Off-Year Re-Pricing for Innovative Drugs, HTA Use in Reimbursement Decisions in 2020
February 20, 2020
- FPMAJ Creates Scheme to Deal with Drug Supply Disruptions; Companies to Set Up “Supply Adjustment Teams”
February 12, 2020
- Drug Formularies Won’t Invade Doctors’ Rights to Prescribe: Payer Rep
February 10, 2020
- RAD-AR Council Accelerating Initiative to Prepare Medication Guides in English toward Tokyo 2020 Olympic and Paralympic Games
February 6, 2020
- Insurance Association to Send Copayment Differences Notification to 15 Year-Old and Over as well to Achieve 80% Generic Target
February 6, 2020
- Japan Red Cross Set to Push Formularies at All Group Hospitals, Despite Medical Fee Plan Dropped
February 5, 2020
- JPMA, Tohoku Medical Megabank to Start Collaborative Research on Preemptive Health
January 30, 2020
- JPMA Wants Revamped System for New Drug Evaluation, Improved Process in 2022 Reform
January 29, 2020
- Generic Industry Will Need Strategies Beyond Core Business for “Post-80%” Era: JGA President
January 23, 2020
- Revoke Conditional OK for Stemirac: Drug Damage Watchdog
January 23, 2020
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…